<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00222261</url>
  </required_header>
  <id_info>
    <org_study_id>ASCET</org_study_id>
    <nct_id>NCT00222261</nct_id>
  </id_info>
  <brief_title>Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.</brief_title>
  <acronym>ASCET</acronym>
  <official_title>Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ullevaal University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Norwegian Council for Cardiovascular Diseases.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ada and Hagbart Waages Humanitarian and Charity Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alf and Aagot Helgesens Research Foundation.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the ASCET study, 1000 patients with documented coronary heart disease will be randomized
      to either continued treatment with aspirin 160 mg/d or change to clopidogrel 75mg/d. Clinical
      endpoints will be recorded for at least 2 years and related to the initial aspirin response,
      assessed by the PFA-100® method, to investigate whether aspirin non-responders have higher
      composite event rate than responders or whether Clopidogrel treatment in patients
      non-responsive to aspirin will reduce their risk of future clinical events. The clinical
      events are the composite of unstable angina, myocardial infarction, stroke or death.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Aspirin is widely used as an antiplatelet drug in patients with coronary heart
      disease. Despite documented clinical benefit, many patients on aspirin still experience
      severe cardiovascular events. Several laboratory reports have shown lack of platelet
      inhibition in 5-40% of aspirin-treated patients, and the term aspirin resistance has been
      introduced. The clinical relevance of these laboratory findings is, however, still unknown.
      New antiplatelet drugs have been developed, and the adenosin diphosphate (ADP) receptor
      inhibitor clopidogrel has at least the same efficacy as aspirin with an acceptable safety
      profile. Laboratory methods for determination of platelet reactivity and treatment efficacy
      have been complicated and time consuming. New methodologies, like the PFA-100® system, have
      made such analyses more suitable for clinical use.

      Design: In the ASCET study, 1000 patients with documented coronary heart disease will be
      randomized to either continued treatment with aspirin 160 mg/d or change to clopidogrel
      75mg/d after initial determination of their platelet reactivity while on aspirin treatment.
      Clinical endpoints will be recorded for at least 2 years and related to the initial aspirin
      response.

      Scand Cardiovasc J. 2004 Dec;38(6):353-6.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Unstable angina with ECG changes or raised levels of cardiac markers not to be classified as a myocardial infarction</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Instent restenosis and/or thrombosis detected by coronary angiography.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1001</enrollment>
  <condition>Coronary Heart Disease</condition>
  <condition>Angina Pectoris</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>1, aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin 160 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2, clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel 75 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <description>Aspirin 160 mg once daily for two years</description>
    <arm_group_label>1, aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>clopidogrel 75 mg once daily for two years</description>
    <arm_group_label>2, clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable, symptomatic coronary heart disease, verified by coronary angiography, being
             treated with angioplasty/stent implantation (PCI) or not.

        Exclusion Criteria:

          -  Indication for warfarin treatment.

          -  Indication for or contraindication to the study drugs.

          -  Pregnancy or breast-feeding.

          -  Malignancy that may interfere with life expectancy.

          -  Psychiatric disease, mental retardation, dementia, drug abuse, alcoholism or
             conditions that can severely reduce compliance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alf-Aage R. Pettersen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Cardiology, Ullevaal University Hospital, Oslo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harald Arnesen, M.D. Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Center for Clinical Cardiovascular Research, Ullevaal University Hospital, Oslo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ingebjorg Seljeflot, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Center for Clinical Cardiovascular Research, Ullevaal University Hospital, Oslo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Abdelnoor, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Center for Clinical Cardiovascular Research, Ullevaal University Hospital, Oslo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arne Westheim, M.D. Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Dept. of Cardiology, Ullevaal University Hospital, Oslo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ullevaal University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 Jan 12;324(7329):71-86. Erratum in: BMJ 2002 Jan 19;324(7330):141.</citation>
    <PMID>11786451</PMID>
  </reference>
  <reference>
    <citation>Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol. 1995 Mar;11(3):221-7.</citation>
    <PMID>7889440</PMID>
  </reference>
  <reference>
    <citation>Grotemeyer KH. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb Res. 1991 Sep 15;63(6):587-93.</citation>
    <PMID>1780803</PMID>
  </reference>
  <reference>
    <citation>Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001 Aug 1;88(3):230-5.</citation>
    <PMID>11472699</PMID>
  </reference>
  <reference>
    <citation>Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, Brace LD. Development of aspirin resistance in persons with previous ischemic stroke. Stroke. 1994 Dec;25(12):2331-6.</citation>
    <PMID>7974569</PMID>
  </reference>
  <reference>
    <citation>Hurlen M, Seljeflot I, Arnesen H. The effect of different antithrombotic regimens on platelet aggregation after myocardial infarction. Scand Cardiovasc J. 1998;32(4):233-7.</citation>
    <PMID>9802142</PMID>
  </reference>
  <reference>
    <citation>De Gaetano G, Cerletti C. Aspirin resistance: a revival of platelet aggregation tests? J Thromb Haemost. 2003 Sep;1(9):2048-50.</citation>
    <PMID>12941050</PMID>
  </reference>
  <reference>
    <citation>Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost. 2003 Aug;1(8):1710-3. Review.</citation>
    <PMID>12911581</PMID>
  </reference>
  <reference>
    <citation>Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res. 1993 Sep 1;71(5):397-403.</citation>
    <PMID>8236166</PMID>
  </reference>
  <reference>
    <citation>Buchanan MR, Schwartz L, Bourassa M, Brister SJ, Peniston CM; BRAT Investigators. Results of the BRAT study--a pilot study investigating the possible significance of ASA nonresponsiveness on the benefits and risks of ASA on thrombosis in patients undergoing coronary artery bypass surgery. Can J Cardiol. 2000 Nov;16(11):1385-90.</citation>
    <PMID>11109035</PMID>
  </reference>
  <reference>
    <citation>Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003 Mar 19;41(6):961-5. Erratum in: J Am Coll Cardiol. 2006 Nov 7;48(9):1918.</citation>
    <PMID>12651041</PMID>
  </reference>
  <reference>
    <citation>CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996 Nov 16;348(9038):1329-39.</citation>
    <PMID>8918275</PMID>
  </reference>
  <reference>
    <citation>Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002 Sep 26;347(13):969-74.</citation>
    <PMID>12324552</PMID>
  </reference>
  <reference>
    <citation>Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res. 2002 Oct 1;108(1):37-42.</citation>
    <PMID>12586130</PMID>
  </reference>
  <reference>
    <citation>Pettersen AA, Seljeflot I, Abdelnoor M, Arnesen H. Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. Scand Cardiovasc J. 2004 Dec;38(6):353-6.</citation>
    <PMID>15804802</PMID>
  </reference>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>March 22, 2011</last_update_submitted>
  <last_update_submitted_qc>March 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Alf-Aage R Pettersen, MD</name_title>
    <organization>Ullevaal University Hospital, Oslo, Norway</organization>
  </responsible_party>
  <keyword>antiplatelet therapy</keyword>
  <keyword>aspirin non-responders</keyword>
  <keyword>aspirin resistance</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>coronary heart disease</keyword>
  <keyword>stable angina pectoris</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

